OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
| 1.01 | |
| 1.05 | |
| - | |
| 1.07 | |
| 1.01 | |
| 0.8075-2.12 | |
| 35 528 K | |
| 33 836 K | |
| 0 | |
| -3.379 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary shareSimultaneous extinguishment of $4.20M of payables by issuing 2,766,667...
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.S...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
